EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH (EEJPH)

ISSN: 2992-4081 ©EEJPH Publications

Volume 6 Issue 2 2024

Assessing the Effectiveness of Immunotherapy in Improving Survival Rates for Advanced Melanoma Patients

Omeye Francis I.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

Melanoma is a highly aggressive form of skin cancer with a poor prognosis in advanced stages. Traditional treatments such as chemotherapy and radiation are often ineffective for patients with metastatic melanoma, highlighting the urgent need for more effective therapies. Immunotherapy, particularly immune checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4, has emerged as a transformative treatment strategy, significantly improving survival rates in advanced melanoma patients. This review explored the mechanisms of action of immunotherapy, particularly the role of PD-1/PD-L1 and CTLA-4 inhibitors, and examined key clinical trials demonstrating their efficacy. Landmark studies such as the KEYNOTE-006 and CheckMate 067 trials have shown remarkable improvements in overall survival (OS) and progression-free survival (PFS) with immune checkpoint inhibitors, establishing them as standard first-line treatments. Combination therapies involving PD-1 inhibitors with CTLA-4 inhibitors have further enhanced survival outcomes, although they are associated with higher rates of immune-related adverse events. Despite these advancements, challenges persist, including patient variability in response, the need for predictive biomarkers, and the financial burden of treatment. This review synthesized current evidence and discusses the ongoing research focused on optimizing immunotherapy regimens and overcoming treatment resistance. Methodologically, this article employed a comprehensive literature review approach, analyzing clinical trials, survival data, and safety profiles to evaluate the effectiveness of immunotherapy in improving survival rates for advanced melanoma patients.

Keywords: Immunotherapy, Advanced Melanoma, Immune Checkpoint Inhibitors, Survival Rates, Clinical Trials.

INTRODUCTION

Melanoma, a malignant tumor originating from melanocytes in the skin, is one of the most aggressive and life-threatening forms of cancer [1, 2]. The incidence of melanoma has increased globally in recent decades, and it is responsible for a significant proportion of skin cancer-related deaths. While early-stage melanoma can often be treated successfully with surgery, the prognosis for patients with advanced melanoma is poor, with a high rate of metastasis and resistance to conventional therapies such as chemotherapy and radiation. This highlights the urgent need for more effective treatment options for advanced melanoma.

In recent years, immunotherapy has emerged as a transformative approach for treating advanced melanoma [3, 4]. Unlike traditional therapies that target cancer cells directly, immunotherapy works by stimulating the body's immune system to recognize and destroy tumor cells. The success of immunotherapies, particularly immune checkpoint inhibitors, has led to a paradigm shift in the treatment of advanced melanoma. Key immune checkpoint inhibitors, including those targeting PD-1/PD-L1 and CTLA-4 pathways, have shown remarkable efficacy in improving survival rates and achieving durable responses in patients with metastatic melanoma [5, 6].

This review aims to assess the effectiveness of immunotherapy in improving survival outcomes for patients with advanced melanoma. By examining the mechanisms of action, clinical trial results, survival data, and safety profiles of immune checkpoint inhibitors, the review will explore how these therapies have impacted overall survival and

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

progression-free survival in this patient population. Additionally, it will address the challenges of treatment resistance, immune-related adverse events, and the need for predictive biomarkers. The goal is to provide an in-depth evaluation of the current evidence, identify gaps in knowledge, and offer insights into the future directions of immunotherapy in melanoma treatment.

MECHANISMS OF IMMUNOTHERAPY IN MELANOMA TREATMENT

Immunotherapy represents a class of treatments that harness the body's immune system to fight cancer [7, 8]. In the context of melanoma, immunotherapy has gained significant attention due to its ability to target the immune checkpoint pathways that prevent the immune system from attacking cancer cells. Two major classes of immune checkpoint inhibitors, which have revolutionized the treatment of advanced melanoma, include immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) and its ligand (PD-L1), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitors.

i. **PD-1/PD-L1 Inhibitors:** PD-1 is a receptor found on T-cells that, when bound by its ligand PD-L1, inhibits T-cell activation, allowing cancer cells to evade immune surveillance [9]. The inhibition of PD-1 or PD-L1 restores T-cell activity against tumor cells. Pembrolizumab (Keytruda) and nivolumab (Opdivo) are the two most widely used PD-1 inhibitors in melanoma therapy. These drugs have demonstrated remarkable efficacy, particularly in patients with advanced melanoma.

ii. **CTLA-4 Inhibitors:** CTLA-4 is another immune checkpoint receptor that negatively regulates T-cell activation [10]. Ipilimumab (Yervoy), an anti-CTLA-4 monoclonal antibody, works by blocking this inhibitory signal, enhancing T-cell activation and promoting an immune response against the tumor. The combination of ipilimumab with PD-1 inhibitors has shown enhanced survival benefits compared to monotherapy.

The synergy between these checkpoint inhibitors underscores the rationale for combination immunotherapy, which has been shown to improve treatment outcomes in advanced melanoma patients by enabling a more robust and sustained immune response.

CLINICAL EVIDENCE SUPPORTING IMMUNOTHERAPY IN ADVANCED MELANOMA

The clinical development of immunotherapy for melanoma has been driven by several landmark studies and clinical trials that have evaluated the efficacy and survival benefits of these treatments. The following discussion focuses on the major trials and their contributions to our understanding of immunotherapy's role in improving survival rates in advanced melanoma.

i. Keynote-006 Trial: Pembrolizumab vs. Ipilimumab: The KEYNOTE-006 trial was a pivotal phase III trial that compared pembrolizumab (a PD-1 inhibitor) to ipilimumab (a CTLA-4 inhibitor) in patients with advanced melanoma [11, 12]. The results of this trial were groundbreaking, showing that pembrolizumab significantly improved progression-free survival (PFS) and overall survival (OS) compared to ipilimumab. At 2 years, the overall survival rate in the pembrolizumab group was 55%, compared to 43% in the ipilimumab group. The safety profile of pembrolizumab was also more favorable, with fewer severe adverse events. This trial established pembrolizumab as a first-line treatment option for patients with advanced melanoma, particularly those with high PD-L1 expression.

ii. Checkmate 067 Trial: Nivolumab + Ipilimumab Combination Therapy: The CheckMate 067 trial examined the efficacy of nivolumab (a PD-1 inhibitor) in combination with ipilimumab (a CTLA-4 inhibitor) versus either monotherapy in patients with advanced melanoma [13]. The combination therapy was found to significantly improve overall survival compared to either agent alone. At 3 years, the overall survival rate in the combination therapy group was 58%, compared to 52% in the nivolumab-only group and 34% in the ipilimumab-only group. The combination regimen led to higher rates of durable responses, including complete responses, and has been considered a breakthrough in the treatment of advanced melanoma. However, the combination therapy also carried higher rates of severe adverse events, including autoimmune disorders, which necessitated careful patient monitoring.

iii. COMBI-v Trial: Combination of Vemurafenib and Cobimetinib: Although not a part of immunotherapy directly, the combination of targeted therapy using BRAF inhibitors and MEK inhibitors (such as vemurafenib and cobimetinib) has demonstrated improved survival in patients with advanced melanoma harboring BRAF V600 mutations. The COMBI-v trial, which evaluated the combination of vemurafenib and cobimetinib, showed significant improvements in progression-free survival and overall survival in patients with BRAF-mutant advanced melanoma [14, 15]. While targeted therapies do not harness the immune system like immunotherapies, they have become a standard part of the treatment armamentarium for melanoma, particularly in patients with BRAF mutations.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

iv. **Ongoing Clinical Trials and Combination Strategies:** Several ongoing trials are exploring the potential for improving survival rates through combination therapies involving immune checkpoint inhibitors, targeted therapies, and vaccines. The combination of PD-1 inhibitors with BRAF/MEK inhibitors or vaccines such as the talimogene laherparepvec (T-VEC) is under investigation to evaluate synergistic effects and long-term survival benefits [16, 17]. Moreover, new strategies involving other immune modulators, including cytokine therapies and oncolytic virotherapy, are being actively explored.

SURVIVAL OUTCOMES AND LONG-TERM EFFICACY

The ultimate measure of treatment effectiveness is its impact on overall survival. Clinical trials of immune checkpoint inhibitors and combination therapies have demonstrated that immunotherapy significantly improves overall survival in patients with advanced melanoma, with some patients experiencing long-term durable responses.

Patients treated with pembrolizumab or nivolumab have shown remarkable durability of response, with many experiencing survival well beyond the expected outcomes for advanced melanoma. The KEYNOTE-006 trial and Checkmate 067 trial demonstrated that a proportion of patients treated with PD-1 inhibitors or combination therapy achieved long-term survival, with some patients remaining in remission for several years following treatment. This is a notable shift from previous melanoma therapies, where survival rates were substantially lower.

Long-term follow-up studies have shown that patients who respond to immunotherapy have the potential for ongoing remission and improved quality of life, even in the setting of advanced metastatic disease. However, a subset of patients fails to respond to immunotherapy or experiences disease progression after an initial response, underscoring the need for better predictive biomarkers and individualized treatment strategies.

CHALLENGES AND LIMITATIONS

While immunotherapy represents a breakthrough in the treatment of advanced melanoma, it is not without challenges. Not all patients respond to immunotherapy, and the reasons for this variability remain poorly understood. Biomarkers such as PD-L1 expression and tumor mutational burden (TMB) have been proposed as potential predictors of response, but they have not been universally accepted or validated across all studies.

Moreover, immune-related adverse events (irAEs) remain a significant concern. These adverse effects, which arise due to the activation of the immune system, can affect various organs, including the skin, liver, lungs, and endocrine glands. The management of these adverse events requires close monitoring and prompt intervention, often involving the use of immunosuppressive therapies. The high incidence of irAEs associated with combination therapies, particularly ipilimumab and nivolumab, is a limiting factor for many patients, especially those with preexisting autoimmune conditions.

The cost of immunotherapy is another consideration. Immunotherapy drugs such as pembrolizumab and nivolumab are expensive, and the long duration of treatment required for some patients can result in a significant financial burden. While these treatments offer substantial survival benefits, access to them may be limited in certain settings due to financial constraints or insurance coverage limitations.

CONCLUSION

Immunotherapy has revolutionized the treatment of advanced melanoma, offering substantial improvements in survival rates and quality of life for patients. The use of PD-1/PD-L1 inhibitors and CTLA-4 inhibitors has shown impressive clinical results, with many patients experiencing long-term survival and durable responses. Combination therapies, including the use of both immune checkpoint inhibitors and targeted therapies, have further enhanced survival outcomes.

Despite these successes, challenges remain, including variability in patient response, the management of immune-related adverse events, and the high cost of treatment. Ongoing research into biomarkers, combination strategies, and the underlying mechanisms of immune resistance will be essential for further improving treatment outcomes and expanding the benefits of immunotherapy to a broader range of patients. In conclusion, immunotherapy has significantly changed the prognosis for patients with advanced melanoma, but continued efforts are needed to optimize treatment regimens, predict patient responses, and ensure equitable access to these life-saving therapies. The future of melanoma treatment lies in the refinement of immunotherapeutic strategies and the development of personalized medicine approaches tailored to the individual needs of patients.

REFERENCES

1. Pecorelli, A., Valacchi, G.: Oxidative-Stress-Sensitive microRNAs in UV-Promoted Development of Melanoma. Cancers. 14, 3224 (2022). https://doi.org/10.3390/cancers14133224
2. Wróblewska-Łuczka, P., Cabaj, J., Bargieł, J., Łuszczki, J.J.: Anticancer effect of terpenes: focus on malignant melanoma. Pharmacol. Rep. 75, 1115–1125 (2023). https://doi.org/10.1007/s43440-023-00512-1
3. Jenkins, R.W., Fisher, D.E.: Treatment of Advanced Melanoma in 2020 and Beyond. Journal of Investigative Dermatology. 141, 23–31 (2021). https://doi.org/10.1016/j.jid.2020.03.943

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

4. Valdez-Salazar, F., Jiménez-Del Rio, L.A., Padilla-Gutiérrez, J.R., Valle, Y., Muñoz-Valle, J.F., Valdés-Alvarado, E.: Advances in Melanoma: From Genetic Insights to Therapeutic Innovations. Biomedicines. 12, 1851 (2024). https://doi.org/10.3390/biomedicines12081851
5. Willsmore, Z.N., Coumbe, B.G.T., Crescioli, S., Reci, S., Gupta, A., Harris, R.J., Chenoweth, A., Chauhan, J., Bax, H.J., McCraw, A., Cheung, A., Osborn, G., Hoffmann, R.M., Nakamura, M., Laddach, R., Geh, J.L.C., MacKenzie-Ross, A., Healy, C., Tsoka, S., Spicer, J.F., Josephs, D.H., Papa, S., Lacy, K.E., Karagiannis, S.N.: Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. European Journal of Immunology. 51, 544–556 (2021). https://doi.org/10.1002/eji.202048747
6. Ziogas, D.C., Theocharopoulos, C., Lialios, P.-P., Foteinou, D., Koumprentziotis, I.-A., Xynos, G., Gogas, H.: Beyond CTLA-4 and PD-1 Inhibition: Novel Immune Checkpoint Molecules for Melanoma Treatment. Cancers. 15, 2718 (2023). https://doi.org/10.3390/cancers15102718
7. Liu, D., Che, X., Wang, X., Ma, C., Wu, G.: Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. Pharmaceuticals. 16, 1384 (2023). https://doi.org/10.3390/ph16101384
8. Raghani, N.R., Chorawala, M.R., Mahadik, M., Patel, R.B., Prajapati, B.G., Parekh, P.S.: Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol. 41, 51 (2024). https://doi.org/10.1007/s12032-023-02280-7
9. Munari, E., Mariotti, F.R., Quatrini, L., Bertoglio, P., Tumino, N., Vacca, P., Eccher, A., Ciompi, F., Brunelli, M., Martignoni, G., Bogina, G., Moretta, L.: PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects. International Journal of Molecular Sciences. 22, 5123 (2021). https://doi.org/10.3390/ijms22105123
10. Zhang, H., Dai, Z., Wu, W., Wang, Z., Zhang, N., Zhang, L., Zeng, W.-J., Liu, Z., Cheng, Q.: Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 40, 184 (2021). https://doi.org/10.1186/s13046-021-01987-7
11. Long, G.V., Carlino, M.S., McNeil, C., Ribas, A., Gaudy-Marqueste, C., Schachter, J., Nyakas, M., Kee, D., Petrella, T.M., Blaustein, A., Lotem, M., Arance, A.M., Daud, A.I., Hamid, O., Larkin, J., Yao, L., Singh, R., Lal, R., Robert, C.: Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Annals of Oncology. (2024). https://doi.org/10.1016/j.annonc.2024.08.2330
12. Robert, C., Carlino, M.S., McNeil, C., Ribas, A., Grob, J.-J., Schachter, J., Nyakas, M., Kee, D., Petrella, T.M., Blaustein, A., Lotem, M., Arance, A., Daud, A.I., Hamid, O., Larkin, J., Anderson, J., Krepler, C., Grebennik, D., Long, G.V.: Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma. JCO. 41, 3998–4003 (2023). https://doi.org/10.1200/JCO.22.01599
13. Hodi, F.S., Chapman, P.B., Sznol, M., Lao, C.D., Gonzalez, R., Smylie, M., Daniels, G.A., Thompson, J.A., Kudchadkar, R., Sharfman, W., Atkins, M., Spigel, D.R., Pavlick, A., Monzon, J., Kim, K.B., Ernst, S., Khushalani, N.I., van Dijck, W., Lobo, M., Hogg, D.: Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Research. 31, 67 (2021). https://doi.org/10.1097/CMR.0000000000000708
14. Ascierto, P.A., Dréno, B., Larkin, J., Ribas, A., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Hsu, J., Jones, S., Li, H., McKenna, E., Voulgari, A., McArthur, G.A.: 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation–Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clinical Cancer Research. 27, 5225–5235 (2021). https://doi.org/10.1158/1078-0432.CCR-21-0809
15. Berking, C., Livingstone, E., Debus, D., Loquai, C., Weichenthal, M., Leiter, U., Kiecker, F., Mohr, P., Eigentler, T.K., Remy, J., Schober, K., Heppt, M.V., von Wasielewski, I., Schadendorf, D., Gutzmer, R.: COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma. Cancers. 15, 4436 (2023). https://doi.org/10.3390/cancers15184436
16. Shalhout, S.Z., Miller, D.M., Emerick, K.S., Kaufman, H.L.: Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 20, 160–177 (2023). https://doi.org/10.1038/s41571-022-00719-w
17. Marconcini, R., Pezzicoli, G., Stucci, L.S., Sergi, M.C., Lospalluti, L., Porta, C., Tucci, M.: Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. Human Vaccines & Immunotherapeutics. (2022)

CITE AS: Omeye Francis I. (2024). Assessing the Effectiveness of Immunotherapy in Improving Survival Rates for Advanced Melanoma Patients. EURASIAN EXPERIMENT JOURNAL OF PUBLIC HEALTH, 6(2): 22-25.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited